JP7446322B2 - アルツハイマー病を治療する方法 - Google Patents
アルツハイマー病を治療する方法 Download PDFInfo
- Publication number
- JP7446322B2 JP7446322B2 JP2021547654A JP2021547654A JP7446322B2 JP 7446322 B2 JP7446322 B2 JP 7446322B2 JP 2021547654 A JP2021547654 A JP 2021547654A JP 2021547654 A JP2021547654 A JP 2021547654A JP 7446322 B2 JP7446322 B2 JP 7446322B2
- Authority
- JP
- Japan
- Prior art keywords
- hydroxypropyl
- cyclodextrin
- composition
- human patient
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752131P | 2018-10-29 | 2018-10-29 | |
| US62/752,131 | 2018-10-29 | ||
| US201962885053P | 2019-08-09 | 2019-08-09 | |
| US62/885,053 | 2019-08-09 | ||
| PCT/US2019/057784 WO2020092107A1 (en) | 2018-10-29 | 2019-10-24 | Methods for treating alzheimer's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022509358A JP2022509358A (ja) | 2022-01-20 |
| JP2022509358A5 JP2022509358A5 (cg-RX-API-DMAC7.html) | 2022-10-28 |
| JP7446322B2 true JP7446322B2 (ja) | 2024-03-08 |
Family
ID=68583503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547654A Active JP7446322B2 (ja) | 2018-10-29 | 2019-10-24 | アルツハイマー病を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11925659B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873604B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7446322B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210084480A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112996562A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021008139A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3114021C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2992137T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3873604T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020092107A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016276774A1 (en) | 2015-06-10 | 2018-01-18 | Vtesse, Inc. | Hydroxypropyl beta-cyclodextrin compositions and methods |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| US11466008B2 (en) | 2017-09-18 | 2022-10-11 | Eip Pharma, Llc | Co-crystals of neflamapimod (VX-745) |
| AU2020204925B2 (en) | 2019-01-03 | 2025-11-20 | Cyclarity Therapeutics, Inc. | Cyclodextrin dimers, compositions thereof, and uses thereof |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| AU2021284155A1 (en) * | 2020-06-02 | 2023-01-05 | National University Of Singapore | Compositions, their uses in therapy and methods thereof |
| WO2022051631A1 (en) | 2020-09-03 | 2022-03-10 | University Of Notre Dame Du Lac | Therapy to stimulate hippocampal neural progenitors and adult neurogenesis |
| CA3200988A1 (en) * | 2020-11-06 | 2022-05-12 | John Jahangir Alam | Treatment of gait dysfunction in neurodegenerative disease |
| WO2022099094A1 (en) * | 2020-11-06 | 2022-05-12 | Eip Pharma, Inc. | Compositions and methods for treating depression |
| WO2022197640A1 (en) * | 2021-03-14 | 2022-09-22 | Massachusetts Institute Of Technology | Apoe4 impairs myelination via altered cholesterol biosynthesis and transport in neuronal cells |
| EP4433828A1 (en) * | 2021-11-18 | 2024-09-25 | Vib Vzw | Improved gamma-secretase inhibitor screening assays |
| JP2025506676A (ja) | 2022-02-18 | 2025-03-13 | ベレン セラピューティクス ピー.ビー.シー. | ヒドロキシプロピル-ベータ-シクロデキストリンの組成物及びその精製方法 |
| WO2023191425A1 (ko) * | 2022-03-28 | 2023-10-05 | 주식회사 비엔에이치리서치 | 약물의 전기생리학적 스크리닝 방법 |
| CN114569742B (zh) * | 2022-05-09 | 2022-07-19 | 北京剂泰医药科技有限公司 | 一种组合物及其制备方法和应用 |
| KR20250024808A (ko) * | 2022-06-13 | 2025-02-19 | 베렌 테라퓨틱스 피.비.씨. | 하이드록시프로필-베타-사이클로덱스트린 제조를 위한 시스템 및 방법 |
| CA3263540A1 (en) * | 2022-07-29 | 2024-02-01 | Anavex Life Sciences Corp. | Compositions and methods for the prevention of cognitive decline caused by degenerative diseases |
| US20260124236A1 (en) * | 2022-09-30 | 2026-05-07 | Cyclo Therapeutics, Inc. | Methods for treating early alzheimer’s disease |
| WO2025214478A1 (zh) * | 2024-04-12 | 2025-10-16 | 北京华昊中天生物医药股份有限公司 | 一种优替德隆药物组合物及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017500310A (ja) | 2013-12-13 | 2017-01-05 | ロケット フレールRoquette Freres | Hdlコレステロール値を上昇させることによって疾病を治療かつ/または予防する、メチルシクロデキストリンをベースとする組成物 |
| JP2017517528A (ja) | 2014-06-12 | 2017-06-29 | ユニバーシティ オブ ノートルダム デュ ラック | 神経疾患および大脳損傷の処置のための組成物および方法 |
| US20180085392A1 (en) | 2015-04-17 | 2018-03-29 | Sens Research Foundation, Inc. | Cyclodextrin compounds for the prevention and treatment of aging |
| JP2018517046A (ja) | 2015-06-10 | 2018-06-28 | ビテス, インコーポレイテッド | ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3346123A1 (de) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US4877778A (en) | 1987-07-01 | 1989-10-31 | The Children's Medical Center Corporation | Method of enhancing lipophile transport using cyclodextrin derivatives |
| US5569756A (en) | 1995-03-21 | 1996-10-29 | American Maize-Products Company | Purification of chemically modified cyclodextrins |
| US8883494B2 (en) | 2003-11-14 | 2014-11-11 | Adil A. KHAN | In vitro model for neuronal death |
| KR101530050B1 (ko) | 2007-03-02 | 2015-06-22 | 주식회사 노브메타파마 | 알츠하이머 질환 및 치매를 치료하기 위한 조성물 및 방법 |
| WO2013155485A2 (en) | 2012-04-13 | 2013-10-17 | Alessia Fornoni | Method of using cyclodextrin |
| CA2880880C (en) | 2012-08-03 | 2021-01-26 | John Mckew | Cyclodextrin for the treatment of lysosomal storage diseases |
| EP3432880A4 (en) * | 2016-03-20 | 2019-12-11 | Asdera LLC | USE OF CYCLODEXTRINS TO REDUCE ENDOCYTOSIS IN MALIGNES AND NEURODEEGENERATIVE DISEASES |
-
2019
- 2019-10-24 EP EP19805439.7A patent/EP3873604B1/en active Active
- 2019-10-24 JP JP2021547654A patent/JP7446322B2/ja active Active
- 2019-10-24 US US17/289,137 patent/US11925659B2/en active Active
- 2019-10-24 WO PCT/US2019/057784 patent/WO2020092107A1/en not_active Ceased
- 2019-10-24 BR BR112021008139-9A patent/BR112021008139A2/pt unknown
- 2019-10-24 KR KR1020217013055A patent/KR20210084480A/ko not_active Ceased
- 2019-10-24 CA CA3114021A patent/CA3114021C/en active Active
- 2019-10-24 ES ES19805439T patent/ES2992137T3/es active Active
- 2019-10-24 CN CN201980071651.0A patent/CN112996562A/zh active Pending
- 2019-10-24 PT PT198054397T patent/PT3873604T/pt unknown
-
2024
- 2024-01-29 US US18/425,707 patent/US20240415871A1/en not_active Abandoned
-
2025
- 2025-06-09 US US19/232,726 patent/US20250302864A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017500310A (ja) | 2013-12-13 | 2017-01-05 | ロケット フレールRoquette Freres | Hdlコレステロール値を上昇させることによって疾病を治療かつ/または予防する、メチルシクロデキストリンをベースとする組成物 |
| JP2017517528A (ja) | 2014-06-12 | 2017-06-29 | ユニバーシティ オブ ノートルダム デュ ラック | 神経疾患および大脳損傷の処置のための組成物および方法 |
| US20180085392A1 (en) | 2015-04-17 | 2018-03-29 | Sens Research Foundation, Inc. | Cyclodextrin compounds for the prevention and treatment of aging |
| JP2018517046A (ja) | 2015-06-10 | 2018-06-28 | ビテス, インコーポレイテッド | ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法 |
Non-Patent Citations (10)
| Title |
|---|
| AUTOPHAGY,2018年,14(7),pp.1129-1154 |
| Free Radical Biology and Medicine,2018年,120,S79, P-114 |
| http://dx.doi.org/10.5772/intechopen.71970[検索日:2023年9月6日],2017年 |
| Human Molecular Genetics,2017年,26(5),pp.843-859 |
| IRYO,71(3),2017年,pp.132-137 |
| J. Exp. Med.,2013年,209(13),pp.2501-2513 |
| Journal of Drug Targeting,2009年,17(2),pp.168-179 |
| Journal of Pharmaceutical Sciences,2016年,105,pp.2372-2380 |
| Molecules,2016年,21,1748 (22 pages) |
| Phys. Chem. Chem. Phys.,2016年,18,pp.20476-20485 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2992137T3 (es) | 2024-12-09 |
| US20240415871A1 (en) | 2024-12-19 |
| EP3873604A1 (en) | 2021-09-08 |
| US11925659B2 (en) | 2024-03-12 |
| BR112021008139A2 (pt) | 2021-08-03 |
| CA3114021A1 (en) | 2021-05-07 |
| JP2022509358A (ja) | 2022-01-20 |
| EP3873604B1 (en) | 2024-08-21 |
| WO2020092107A1 (en) | 2020-05-07 |
| PT3873604T (pt) | 2024-10-22 |
| CA3114021C (en) | 2025-05-27 |
| US20220008453A1 (en) | 2022-01-13 |
| KR20210084480A (ko) | 2021-07-07 |
| CN112996562A (zh) | 2021-06-18 |
| US20250302864A1 (en) | 2025-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11925659B2 (en) | Methods for treating Alzheimer's disease | |
| HK1242998A1 (zh) | 治疗法布里病的给药方案 | |
| EP3445369B1 (en) | Vx-745 for use in the treatment of dementia | |
| KR20250078929A (ko) | 알츠하이머병 치료를 위한 면역치료법과 사일로이노시톨 병용 | |
| EP3137097B1 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| CN120051284A (zh) | 用于治疗早期阿尔茨海默病的方法 | |
| WO2020214538A1 (en) | Treatment and prevention of dementia and other neurodegenerative diseases | |
| EP4209222A1 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| AU2015254663B2 (en) | Treatment and prevention of Alzheimer's Disease (AD) | |
| HK40059055B (en) | Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin | |
| HK40059055A (en) | Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin | |
| CA3268619A1 (en) | Methods for treating early alzheimer's disease | |
| US20240016783A1 (en) | Riluzole for the treatment of alzheimer's disease | |
| WO2025228863A1 (en) | Dose regimen for a 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivative | |
| Sharma et al. | Tailoring MAPK Pathways: New Therapeutics Avenues for Managing Alzheimer’s Diseases | |
| US20200289473A1 (en) | Methods of treating neurodegeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221020 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221020 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230906 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230911 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231210 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240130 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240227 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7446322 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |